Propel Bio Management »

Celldex Therapeutics shares owned by Propel Bio Management

Quarter-by-quarter ownership of Celldex Therapeutics (CLDX) shares owned by Propel Bio Management from 13F filings

Historical chart of Propel Bio Management investment in Celldex Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Celldex Therapeutics held by Propel Bio Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Celldex Therapeutics by Propel Bio Management

Quarter filed Position value Share count Share price at filing
2025-09-30 $4.0M 155k 25.87

More positions owned by Propel Bio Management

Plains Gp Holdings Lp-cl Ltd Partnr Int A (PAGP)
Achieve Life Sciences (ACHV)
Akero Therapeutics (AKRO)
Milestone Pharmaceuticals (MIST)
Applied Therapeutics (APLT)
Phathom Pharmaceuticals (PHAT)
Abeona Therapeutics Com New (ABEO)
Delcath Systems Com New (DCTH)
Celldex Therapeutics Com New (CLDX)
Tscan Therapeutics (TCRX)
Compass Pathways Sponsored Ads (CMPS)
Nektar Therapeutics Com New (NKTR)
Jasper Therapeutics Com New (JSPR)
Zevra Therapeutics Com New (ZVRA)
Miragen Therapeutics (VRDN)

View all positions for Propel Bio Management

Top funds holding Celldex Therapeutics

Kynam Capital Management
Wellington Management Company
BlackRock
FMR
Vanguard Group
Point72 Asset Management
Bellevue Group
Commodore Capital
State Street Corporation
Deep Track Capital
Eventide Asset Management
Geode Capital Management
Polar Capital Holdings
Pictet Asset Management Holding SA
Vestal Point Capital

View all funds holding Celldex Therapeutics